Hi Wayne,
Yes, we both highlighted that same quote from the article. :-)
What's worth re-highlighting is that Phylogica have only analysed a handful of the peptides with their second generation libraries and platform enhancements to identify endosomal escape.
Do you remember this presentation highlighting work with Roche?
http://www.phylogica.com/media/PhylogicaTechnologyCapabilities-web-Feb2012.pdf
They've come a long way since then.
Perhaps time in discussion is directly proportional to the size of the deal.
Could not agree more!
Regards,
Tony
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |